-
公开(公告)号：US20150157691A1
公开(公告)日：2015-06-11
申请号：US14561981
申请日：2014-12-05
Applicant: Texas Tech University System
Inventor： Maurizio Chiriva-Internati , Jose A. Figueroa , Everardo Cobos
IPC: A61K38/17 , G01N33/561 , A61K31/337
CPC classification number: A61K38/1732 , A61K31/337 , A61K48/00 , C07K14/4726 , G01N33/57449 , G01N2500/10 , A61K2300/00
Abstract: The present invention includes a method for the treatment of an advanced ovarian cancer, comprising: identifying a patient with advanced ovarian cancer; and administering to the patient an effective amount of truncated, dominant negative form of Galectin-3 sufficient to reduce the advanced ovarian cancer. In certain aspects, the truncated, dominant negative form of Galectin-3 is provided in an amount sufficient to reduce at least one of growth, motility, invasion, angiogenesis, or prevents Akt/NF-κB activation of the ovarian cancer.
Abstract translation: 本发明包括一种治疗晚期卵巢癌的方法，包括：鉴定晚期卵巢癌患者; 并向患者施用足够减少晚期卵巢癌的有效量的截短的，显性阴性形式的Galectin-3。 在某些方面，提供半数优势阴性形式的半乳凝素-3以足以减少生长，运动性，侵袭，血管发生或抑制卵巢癌的Akt / NF-κB活化中的至少一种的量。
-
Patent Agency Ranking
公开(公告)号：US09744212B2
公开(公告)日：2017-08-29
申请号：US15017856
申请日：2016-02-08
Applicant: Texas Tech University System , MandalMed, Inc.
Inventor： Maurizio Chiriva-Internati , Everardo Cobos , Constance John
CPC classification number: A61K38/1732 , A61K31/407 , A61K31/69 , A61K38/05 , A61K38/07 , A61K45/06 , A61K2300/00
Abstract: The present invention provides a novel composition of matter useful for the treatment of neoplastic diseases. The novel composition is synergistic and comprised of galectin-3C in combination with a proteasome inhibitor, the combination having a pharmacologic activity greater than the expected additive effect of its individual components. Other embodiments of the invention provide novel synergistic compositions of galectin-3C with a proteasome inhibitor capable of reducing or overcoming resistance that develops to the proteasome inhibitor or reducing the adverse side effects from the proteasome inhibitor through increasing the therapeutic efficacy of lower doses.
-
3.发明申请Galectin-3 Inhibitor (Gal-3M) is Associated with Additive Anti-Myeloma and Anti-Solid Tumor Effects, Decreased Osteoclastogenesis and Organ Protection when Used in Combination with Proteasome Inhibitors 审中-公开Galectin-3抑制剂（Gal-3M）与添加抗骨髓瘤和抗固体肿瘤作用相关联，当与蛋白酶体抑制剂组合使用时，破骨细胞形成和器官保护减少公开(公告)号：US20160122408A1
公开(公告)日：2016-05-05
申请号：US14992334
申请日：2016-01-11
Applicant: Texas Tech University System
Inventor： Maurizio Chiriva-Internati , Jose A. Figueroa , Everardo Cobos
IPC: C07K14/47
CPC classification number: C07K14/4726 , A61K31/145 , A61K31/27 , A61K31/336 , A61K31/353 , A61K31/4015 , A61K31/407 , A61K31/427 , A61K31/5377 , A61K31/69 , A61K31/713 , A61K38/05 , A61K38/06 , A61K38/07 , A61K38/1732 , A61K45/06 , G01N33/5011 , A61K2300/00 , A61K31/365
Abstract: The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Gaicctin-3 and a proteasome inhibitor.
Abstract translation: 本发明包括用于治疗骨髓瘤的方法，包括鉴定患有骨髓瘤的患者，并向患者施用协同的有效量的截短，显性失活形式的Gaicctin-3和蛋白酶体抑制剂。
-
4.发明申请Galectin-3 Inhibitor (Gal-3M) is Associated with Additive Anti-Myeloma and Anti-Solid Tumor Effects, Decreased Osteoclastogenesis and Organ Protection when Used in Combination with Proteasome Inhibitors 审中-公开Galectin-3抑制剂（Gal-3M）与添加抗骨髓瘤和抗固体肿瘤作用相关联，当与蛋白酶体抑制剂组合使用时，破骨细胞形成和器官保护减少公开(公告)号：US20160122407A1
公开(公告)日：2016-05-05
申请号：US14992173
申请日：2016-01-11
Applicant: Texas Tech University System
Inventor： Maurizio Chiriva-Internati , Jose A. Figueroa , Everardo Cobos
IPC: C07K14/47
CPC classification number: C07K14/4726 , A61K31/145 , A61K31/27 , A61K31/336 , A61K31/353 , A61K31/4015 , A61K31/407 , A61K31/427 , A61K31/5377 , A61K31/69 , A61K31/713 , A61K38/05 , A61K38/06 , A61K38/07 , A61K38/1732 , A61K45/06 , G01N33/5011 , A61K2300/00 , A61K31/365
Abstract: The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Galectin-3 and a proteasome inhibitor.
Abstract translation: 本发明包括用于治疗骨髓瘤的方法，包括鉴定患有骨髓瘤的患者，并向患者施用协同的有效量的半衰期，显性失活形式的Galectin-3和蛋白酶体抑制剂。
-
公开(公告)号：US20160250289A1
公开(公告)日：2016-09-01
申请号：US15017856
申请日：2016-02-08
Applicant: Texas Tech University System
Inventor： Maurizio Chiriva-Internati , Everardo Cobos , Constance John
IPC: A61K38/17 , A61K38/07 , A61K31/407 , A61K45/06 , A61K38/05
CPC classification number: A61K38/1732 , A61K31/407 , A61K31/69 , A61K38/05 , A61K38/07 , A61K45/06 , A61K2300/00
Abstract: The present invention provides a novel composition of matter useful for the treatment of neoplastic diseases. The novel composition is synergistic and comprised of galectin-3C in combination with a proteasome inhibitor, the combination having a pharmacologic activity greater than the expected additive effect of its individual components. Other embodiments of the invention provide novel synergistic compositions of galectin-3C with a proteasome inhibitor capable of reducing or overcoming resistance that develops to the proteasome inhibitor or reducing the adverse side effects from the proteasome inhibitor through increasing the therapeutic efficacy of lower doses.
Abstract translation: 本发明提供了可用于治疗肿瘤性疾病的新物质组合物。 该新型组合物是协同增效的，并且包含半乳凝素-3C与蛋白酶体抑制剂的组合，该组合具有大于其单独成分的预期加成效应的药理活性。 本发明的其它实施方案提供半抗原-3C与蛋白酶体抑制剂的新型协同组合物，其能够通过增加较低剂量的治疗功效降低或克服发展为蛋白酶体抑制剂的抗性或降低蛋白酶体抑制剂的不良副作用。
-
6.发明申请GALECTIN-3 INHIBITOR (GAL-3M) IS ASSOCIATED WITH ADDITIVE ANTI-MYELOMA AND ANTI-SOLID TUMOR EFFECTS, DECREASED OSTEOCLASTOGENESIS AND ORGAN PROTECTION WHEN USED IN COMBINATION WITH PROTEASOME INHIBITORS 审中-公开GALECTIN-3抑制剂（GAL-3M）与添加抗血清和抗固体肿瘤效应有关，当与抗抑郁药组合使用时，减少了OSTEOCLASTOGENESISISIS和ORGAN保护公开(公告)号：US20150216931A1
公开(公告)日：2015-08-06
申请号：US14612757
申请日：2015-02-03
Applicant: Texas Tech University System
Inventor： Maurizio Chiriva-Internati , Jose A. Figueroa , Everardo Cobos
CPC classification number: C07K14/4726 , A61K31/145 , A61K31/27 , A61K31/336 , A61K31/353 , A61K31/4015 , A61K31/407 , A61K31/427 , A61K31/5377 , A61K31/69 , A61K31/713 , A61K38/05 , A61K38/06 , A61K38/07 , A61K38/1732 , A61K45/06 , G01N33/5011 , A61K2300/00 , A61K31/365
Abstract: The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Galectin-3 and a proteasome inhibitor.
Abstract translation: 本发明包括用于治疗骨髓瘤的方法，其包括鉴定患有骨髓瘤的患者，并向患者施用协同的有效量的半衰期，显性失活形式的Galectin-3和蛋白酶体抑制剂。
-
-
-
-
-
Search Results
6
records
(took 0.015 seconds)
